Literature DB >> 20674577

Identification of a novel monoclonal antibody recognizing CD133.

Suresh Kumar Swaminathan1, Michael R Olin, Colleen L Forster, Karen S Santa Cruz, Jayanth Panyam, John R Ohlfest.   

Abstract

Human CD133 (prominin-1), a cell surface glycoprotein, is used as a marker of hematopoietic and neural stem cells. Antibodies that recognize a glycosylation-dependent CD133 epitope have been extensively used for enrichment of tumor initiating cells in a variety of cancers. These currently available antibodies are restricted for use in only a subset of biological assays. We have generated a novel anti-human CD133 monoclonal antibody, using a recombinant protein consisting of highly immunogenic amino acid residues selected from the native CD133 protein as an immunogen. The antibody (identified as clone 7) specifically recognizes the CD133 protein in a variety of immunological applications including Western blot, immunofluorescence, flow cytometry and immunohistochemistry. Further, clone 7 specifically recognizes an unmodified CD133 extracellular domain, and not its glycosylated epitope. In conclusion, the specificity and usefulness in a wide range of applications suggest that clone 7 could be a valuable tool to identify CD133 positive cells as well as to target them for therapy.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20674577     DOI: 10.1016/j.jim.2010.07.007

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  20 in total

Review 1.  Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches.

Authors:  Qin Pan; Qiao Li; Shuang Liu; Ning Ning; Xiaolian Zhang; Yingxin Xu; Alfred E Chang; Max S Wicha
Journal:  Stem Cells       Date:  2015-05-13       Impact factor: 6.277

2.  Immunotoxin targeting CD133(+) breast carcinoma cells.

Authors:  John R Ohlfest; David M Zellmer; Jayanth Panyam; Suresh Kumar Swaminathan; Seunguk Oh; Nate N Waldron; Shoko Toma; Daniel A Vallera
Journal:  Drug Deliv Transl Res       Date:  2013-04       Impact factor: 4.617

3.  Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery.

Authors:  Timothy E Andrews; Dan Wang; Daniel A Harki
Journal:  Drug Deliv Transl Res       Date:  2013-04       Impact factor: 4.617

4.  Identification and characterization of a novel scFv recognizing human and mouse CD133.

Authors:  Suresh Kumar Swaminathan; Lin Niu; Nate Waldron; Steve Kalscheuer; David M Zellmer; Michael R Olin; John R Ohlfest; Daniel A Vallera; Jayanth Panyam
Journal:  Drug Deliv Transl Res       Date:  2013-04       Impact factor: 4.617

5.  Synthesis and antileukemic activities of C1-C10-modified parthenolide analogues.

Authors:  Aaron M Kempema; John C Widen; Joseph K Hexum; Timothy E Andrews; Dan Wang; Susan K Rathe; Frederick A Meece; Klara E Noble; Zohar Sachs; David A Largaespada; Daniel A Harki
Journal:  Bioorg Med Chem       Date:  2015-05-30       Impact factor: 3.641

Review 6.  Drug-Tolerant Persister Cells in Cancer Therapy Resistance.

Authors:  Pavan Kumar Dhanyamraju; Todd D Schell; Shantu Amin; Gavin P Robertson
Journal:  Cancer Res       Date:  2022-07-18       Impact factor: 13.312

7.  Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells.

Authors:  J U Schmohl; M K Gleason; P R Dougherty; J S Miller; D A Vallera
Journal:  Target Oncol       Date:  2016-06       Impact factor: 4.493

8.  Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.

Authors:  Amy P N Skubitz; Elizabeth P Taras; Kristin L M Boylan; Nate N Waldron; Seunguk Oh; Angela Panoskaltsis-Mortari; Daniel A Vallera
Journal:  Gynecol Oncol       Date:  2013-05-27       Impact factor: 5.482

9.  Prominin-1-Radixin axis controls hepatic gluconeogenesis by regulating PKA activity.

Authors:  Hyun Lee; Dong-Min Yu; Jun Sub Park; Hwayeon Lee; Jun-Seok Kim; Hong Lim Kim; Seung-Hoi Koo; Jae-Seon Lee; Sungsoo Lee; Young-Gyu Ko
Journal:  EMBO Rep       Date:  2020-10-08       Impact factor: 8.807

10.  Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer.

Authors:  Nate N Waldron; Dan S Kaufman; Seunguk Oh; Zintis Inde; Melinda K Hexum; John R Ohlfest; Daniel A Vallera
Journal:  Mol Cancer Ther       Date:  2011-08-23       Impact factor: 6.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.